Deal Snapshot
Lilly to Acquire Neurodegeneration Specialist Disarm Therapeutics
Friday 16 October 2020

US-based drugmaker Eli Lilly and Company (NYSE: LLY) has inked a definitive agreement to acquire US-based biotechnology company Disarm Therapeutics, the company said.

Disarm is developing a new class of disease-modifying therapeutics for patients with axonal degeneration.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 16/10/2020

Options